Market Place
Sourcing Support
Silence Therapeutics`s Late-Breaking Zerlasiran Data at AHA 2024
18 Nov 2024 //
BUSINESSWIRE
Silence Therapeutics Reports Q3 2024 Results & Highlights
14 Nov 2024 //
BUSINESSWIRE
Silence Therapeutics to Join Fireside Chat at Jefferies London
13 Nov 2024 //
BUSINESSWIRE
Silence Therapeutics Raises Awareness Of Cardiovascular Risk Factor Lp(a)
29 Aug 2024 //
FIERCE PHARMA
Silence Therapeutics To Webcast At September Investor Conferences
27 Aug 2024 //
BUSINESSWIRE
Silence Therapeutics Reports Q2 2024 Financial Results And Business Highlights
15 Aug 2024 //
BUSINESSWIRE
Silence Announces Positive Results from Ongoing SANRECO Pha1 Study of Divesiran
27 Jun 2024 //
BUSINESSWIRE
Silence breaks phase 1 data on blood disorder prospect
27 Jun 2024 //
FIERCE BIOTECH
Silence Therapeutics Receives $2M Milestone Payment From Hansoh
24 Jun 2024 //
CONTRACT PHARMA
Silence Therapeutics Reports Positive 48-Week Data For Zerlasiran Study
20 Jun 2024 //
BUSINESSWIRE
Silence Therapeutics to Present at Jefferies Global Healthcare Conference
30 May 2024 //
BUSINESSWIRE
Silence Therapeutics Reports Q1 2024 Results, Pipeline Progress
16 May 2024 //
BUSINESSWIRE
Silence To Participate In Fireside Chat At Wainwright Conference
30 Apr 2024 //
BUSINESSWIRE
Silence Therapeutics: Alistair Gray Retiring from Board
29 Apr 2024 //
BUSINESSWIRE
Silence Announces JAMA Publication of Zerlasiran
08 Apr 2024 //
BUSINESSWIRE
Silence loses Mallinckrodt collab, wins in cardiovascular ph. 2
13 Mar 2024 //
FIERCE BIOTECH
Silence Therapeutics to Report Fourth Quarter and Full Year 2023 Results
28 Feb 2024 //
BUSINESSWIRE
Silence Therapeutics Achieves $10M Payment from AstraZeneca Collaboration
23 Feb 2024 //
BUSINESSWIRE
Silence Therapeutics Announces Oversubscribed $120 Million Private Placement
05 Feb 2024 //
BUSINESSWIRE
Silence Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare
31 Jan 2024 //
BUSINESSWIRE
Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments
01 Dec 2023 //
BUSINESSWIRE
Silence Therapeutics to Present at Jefferies London Healthcare Conference
08 Nov 2023 //
BUSINESSWIRE
Silence Therapeutics Announces Results from Phase 1 Study of Zerlasiran
01 Nov 2023 //
BUSINESSWIRE
Silence to Participate in Fireside Chat at Chardan’s 7th Annual Conference
26 Sep 2023 //
BUSINESSWIRE
Silence Therapeutics to Participate in September Investor Conferences
06 Sep 2023 //
BUSINESSWIRE
Silence Therapeutics Achieves $4M in Research Milestone Payments from Hansoh
11 Jul 2023 //
BUSINESSWIRE
Silence Therapeutics to Present at the Jefferies Healthcare Conference
31 May 2023 //
BUSINESSWIRE
Silence Therapeutics Reports First Quarter 2023 Results
16 May 2023 //
BUSINESSWIRE
Silence Therapeutics Achieves $10 MMilestone Payment from AZ Collaboration
04 May 2023 //
BUSINESSWIRE
Silence Therapeutics Earns $10M AZ Milestone in siRNA Alliance
04 May 2023 //
CONTRACT PHARMA
Silence to Participate in Fireside Chat at H.C. Wainwright BioConnect Conference
25 Apr 2023 //
BUSINESSWIRE
Silence Therapeutics to Buyback siRNA Complement Assets
28 Mar 2023 //
BUSINESSWIRE
Silence Appoints Dr. Steven Romano as Incoming Chief Medical Officer
28 Mar 2023 //
BUSINESSWIRE
Silence takes back 2 complement programs from Mallinckrodt
28 Mar 2023 //
FIERCE BIOTECH
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
15 Mar 2023 //
BUSINESSWIRE
Silence to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
02 Mar 2023 //
BUSINESSWIRE
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
08 Feb 2023 //
BUSINESSWIRE
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
12 Jan 2023 //
BUSINESSWIRE
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
BUSINESSWIRE
Silence Therapeutics Reports Third Quarter 2022 Results
10 Nov 2022 //
BUSINESSWIRE
Silence Therapeutics Presents Analysis from SLN360 PI Single Dose Study at AHA
05 Nov 2022 //
BUSINESSWIRE
FDA grants Silence`s drug fast-track tag for a blood cancer
08 Sep 2022 //
FIERCEBIOTECH
Silence Therapeutics Announces Pricing of Underwritten Offering
11 Aug 2022 //
BUSINESSWIRE
Silence Tx to Participate in Fireside Chat at H.C. Wainwright Conference
18 May 2022 //
PRESS RELEASE
Silence Therapeutics Reports First Quarter 2022 Results
16 May 2022 //
BUSINESSWIRE
Silence Therapeutics Achieves $2 Million Research Milestone
25 Apr 2022 //
BUSINESSWIRE
Silence Therapeutics to Present at 21st Annual Needham Virtual Conference
06 Apr 2022 //
PRESS RELEASE
Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study at ACC
03 Apr 2022 //
PRESS RELEASE
Silence To publish Results From SLN360 Phase 1 Study
03 Apr 2022 //
PRESS RELEASE
Silence Tx and Mallinckrodt Submit Clinical Trial Application for SLN501
23 Mar 2022 //
BUSINESSWIRE
Silence Tx Reports Q4 and FY 2021 Results
17 Mar 2022 //
BUSINESSWIRE
Silence Therapeutics to Report Q4 and Full Year 2022 Results
02 Mar 2022 //
BUSINESSWIRE
Another biotech shuffles its C-suite as Silence CEO steps down
22 Feb 2022 //
ENDPTS
Silence Therapeutics Appoints Craig Tooman President and Chief Executive Officer
21 Feb 2022 //
BUSINESSWIRE
Silence Tx Shows Positive Topline Data in SLN360 Phase 1 Ascending Dose Study
09 Feb 2022 //
BUSINESSWIRE
Silence Therapeutics Announces SLN360 Phase 1 Data Accepted at ATC 2022
26 Jan 2022 //
BUSINESSWIRE
Hansoh, J&J, Brii and more—Fierce Pharma Asia
22 Oct 2021 //
FIERCEPHARMA
Silence Therapeutics Provides mRNAi GOLD™ Platform and Pipeline Updates
21 Oct 2021 //
GLOBENEWSWIRE
Chinese powerhouse continues charge into siRNA with Silence pact
15 Oct 2021 //
FIERCEBIOTECH
Silence Achieves Another Research Milestone Payment from Mallinckrodt
28 Apr 2021 //
GLOBENEWSWIRE
